[{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lutris' Ph 1 LUT014 Data for Skin Toxicities Linked with Treatment of Colorectal Cancer with EGFR Inhibitors Published in Cancer Discovery","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"April 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lutris Pharma Doses First U.S. Patients in Phase 2 Trial of LUT014","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"August 2021","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lutris Pharma Receives Notice of Allowance for Key U.S. Patent Application Covering Lead Compound, LUT014, a Novel B-Raf Inhibitor","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","highestDevelopmentStatus":"Phase I\/ Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2022","url1":"","url2":"","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Lutris Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Lutris Pharma Receives FDA Orphan Drug Designation for LUT014 for the Treatment of EGFRI-Induced Acneiform Rash","therapeuticArea":"Dermatology","highestDevelopmentStatus":"Phase II","country":"ISRAEL","productType":"Small molecule","productStatus":"New Molecular Entity","date":"February 2024","url1":"","url2":"","graph1":"Dermatology","graph2":"Phase II"}]
Find Clinical Drug Pipeline Developments & Deals for LUT-014
LUT014 is a novel B-Raf inhibitor, small molecule drug which is applied topically on the skin. It is being evaluated for the treatment of EGFRI-Induced Acneiform Rash.
LUT-RD (LUT014) is designed to balance the destruction of cells in the basal layer of the skin resulting from radiation, by enhancing cell proliferation, thus potentially reversing the effects of radiation dermatitis.
The trial will evaluate the efficacy and safety of two strengths of LUT014 Gel, 0.03% or 0.10%, applied once daily for 4 weeks, compared to placebo, in patients with mCRC who develop Grade 2 EGFR inhibitor-induced acneiform lesions, with a 4-week follow up period.
ALLO-501A, a next-generation anti-CD19 AlloCAR T , eliminates the rituximab recognition domains in ALLO-501, which could allow for use in a broader patient population, including NHL patients with recent rituximab exposure.